Screening
Thoughtful, field-specific content is coming to this collection.
Explore soon →Industry
Where models meet translation
Platforms, partnerships and practical lessons from teams bringing human cell models into discovery.
Biomanufacturing
Thoughtful, field-specific content is coming to this collection.
Explore soon →Technology
Thoughtful, field-specific content is coming to this collection.
Explore soon →PUBLISHED ON HCMX
Latest industry
news
Cartherics and Zucker Institute pair an iPSC cell platform with tissue-factor targeting
A new research and option agreement will test whether Cartherics' engineered, iPSC-derived natural killer cells can be combined with an anti-tissue-factor antibody for solid tumours and endometriosis.
HCMX Editorialnews
bit.bio opens industrial-scale CRISPR screening in human iPSC-derived cells
bit.bio has launched ioScreen, a service intended to give drug-discovery teams access to large CRISPR screens in mature human iPSC-derived cells without building the capability in-house.
HCMX Editorialnews
HeartBeat.bio and Molecular Devices package cardiac organoids for scalable safety studies
The companies have announced two 3D Ready Cardioid Supplement Kits designed to generate beating iPSC-derived cardiac organoids in manual or automated workflows.
HCMX Editorialnews
Bruker takes majority stake in organ-on-chip specialist MIMETAS
Bruker's majority investment in MIMETAS brings high-throughput human tissue and organ-on-chip models alongside multiomics, spatial biology, NMR and imaging technologies.
HCMX Editorialnews
Hopstem secures first Series C close for iPSC-derived neural cell therapy
Hopstem says the first close of its Series C will support clinical development and commercial manufacturing of its iPSC-derived forebrain neural progenitor programme.
HCMX Editorial